October 30, 2024 – Talk Bio

Actionable Insights Powered by AI

GSK Shifts Focus from Acquired Vaccine to Preclinical Successor Due to Increased Competition

9 months ago talkbio0Tagged Affinivax, competition, Increased, MAPS technology, Pneumococcal vaccine, Preclinical Successor, SmithKline Beecham, Vaccines

GSK, vaccine, preclinical successor, increased competition, pneumococcal vaccine, Affinivax, MAPS technology

Biotech Layoffs Continue in 2024: Spero and Pfizer Among Latest to Cut Workforce

9 months ago talkbio0Tagged Biotech Layoffs, Drug Industry, layoffs, Pfizer, Spero

Biotech layoffs, Spero, Pfizer, workforce reduction, 2024 layoffs, pharmaceutical industry, job cuts.

TCT 2024: Johnson & Johnson’s Abiomed Successfully Completes Pivotal Study for Innovative Shrinkable Heart Pump, Impella ECP

9 months ago talkbio0Tagged Abiomed, Approved, High-Risk PCI, Impella, Johnson & Johnson, RNASE3 gene, Shock, Cardiogenic, Shrinkable Heart Pump, Thrombin Time Assay, United States Food and Drug Administration

TCT 2024, Johnson & Johnson, Abiomed, Impella ECP, Shrinkable Heart Pump, High-Risk PCI, Cardiogenic Shock, FDA Approval

Eli Lilly’s Stock Plummets Following Q3 Earnings Miss and Reduced Revenue Forecast

9 months ago talkbio0Tagged Diabetes, Drops - Drug Form, drug sales, earnings, Eli, Eli Lilly, Obesity, Weight-Loss Agents

Eli Lilly, Q3 earnings, revenue forecast, stock drop, diabetes drugs, weight-loss drugs, obesity drug sales

Biogen Expands Portfolio with Neomorph Molecular Glues Deal Worth Up to $1.45 Billion

9 months ago talkbio0Tagged Biogen, biotech, deal, molecular glues, Neomorph, pharmaceutical acquisition

Biogen, Neomorph, Molecular Glues, Biotech Deal, Pharmaceutical Acquisition

Lexicon’s Diabetes Drug Zynquista Faces FDA Scrutiny Again Ahead of Advisory Committee Meeting

9 months ago talkbio0Tagged Advisory Committees, Diabetes, lexicon, regulatory, United States Food and Drug Administration, Zynquista

Lexicon Pharmaceuticals, Zynquista, FDA, diabetes drug, advisory committee, regulatory challenges

Spero Therapeutics Slashes 39% of Workforce Following Phase 2 Antibiotic Trial Failure

9 months ago talkbio0Tagged antibiotic trial, Biotech Layoffs, cash runway extension, Failure (biologic function), Spero Therapeutics

Spero Therapeutics, antibiotic trial failure, workforce reduction, biotech layoffs, cash runway extension

Biogen and Sage Discontinue Plans for Major Depressive Disorder Approval for Zurzuvae

9 months ago talkbio0Tagged Approved, Biogen, Depression, Postpartum, Depressive disorder, United States Food and Drug Administration, Zurzuvae

Biogen, Sage Therapeutics, Zurzuvae, postpartum depression, major depressive disorder, FDA approval

Eli Lilly’s Kisunla Shows Reduced Brain Swelling with Modified Dosing Regimen in Alzheimer’s Patients

9 months ago talkbio0Tagged Alzheimer 's disease, ARIA-E, Cerebral Edema, Changing, dosing, Eli, Eli Lilly, Kisunla, Risk, Treatment Protocols

Eli Lilly, Kisunla, Alzheimer’s disease, brain swelling, modified dosing regimen, ARIA-E risk reduction

Novartis Secures FDA Approval for Scemblix as First-Line Treatment for Newly Diagnosed CML, Anticipates $3B in Peak Sales

9 months ago talkbio0Tagged Approved, first-line, Inhibitor, Myeloid Leukemia, Chronic, Novartis, Scemblix, TTLL5 gene, Tyrosine Kinase Inhibitors [MoA], United States Food and Drug Administration

Novartis, Scemblix, FDA Approval, First-Line Treatment, CML, Chronic Myeloid Leukemia, ASC4FIRST Trial, Tyrosine Kinase Inhibitors, STAMP Inhibitor